company_name,location,website,therapeutic_areas,fit_score,reason_for_fit,num_decision_makers,num_phase2_failed,num_phase3_failed,num_drug_assets
Krystal Biotech,,,oncology,75,"Krystal Biotech's halt in the phase 2 study of KB707 due to unspecified reasons, combined with their focus on oncology, presents a potential opportunity for Convexia to explore rescue strategies. The company's commitment to gene therapy for dermatological diseases aligns with Convexia's interest in innovative treatments with a strong scientific rationale.",5,1,0,1
